Law Firm Investigates Pacira BioSciences Over Shareholder Rights
Monteverde & Associates PC has launched an investigation into Pacira BioSciences amid potential shareholder claims. The M&A-focused class action firm is soliciting investors.
A New York-based securities law firm has announced an investigation into Pacira BioSciences, Inc., the Nasdaq-listed pharmaceutical company trading under the ticker PCRX, according to a statement released October 11, 2026.
Monteverde & Associates PC, led by class action attorney Juan Monteverde, is examining potential claims on behalf of Pacira BioSciences shareholders. The firm said it has recovered millions of dollars for investors in prior cases and was ranked among the top 50 firms in the 2025 ISS Securities Class Action Services Report.
Read more Law Firm Probes Option Care Health Amid Shareholder Concerns →
Shareholder investigations of this nature typically precede formal litigation and are designed to determine whether corporate officers or directors may have breached fiduciary duties — often in connection with a merger, acquisition, or material disclosure failure. The announcement did not specify the precise conduct under review, but the firm's focus on mergers and acquisitions suggests the probe may center on a pending or completed transaction involving Pacira.
Pacira BioSciences specializes in non-opioid pain management therapies and has been an active player in pharmaceutical dealmaking in recent years. Shareholders who held PCRX stock and believe they may have been harmed are being encouraged to contact the firm directly to learn about their legal options before any applicable deadlines.
Investors are advised to consult independent legal counsel to evaluate the merits of any potential claim. Continue reading at All Financial Services & Investing.
